{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.5","value":"2.6"}]}]}],"denomUnitsSelected":"Number of Treatments","denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"57"}],"units":"Number of Treatments"}],"description":"Subjects underwent 3-5 monthly treatments and reported discomfort associated with treatment on a 10-cm visual analogue scale (VAS) of 0 = no pain to 10 = worst possible pain, immediately after each treatment. The outcome presented here is the mean grade of discomfort/pain associated with all treatments. Lower value presents lower treatment-associated discomfort. Since patients received 3-5 monthly treatments these values were collected at each treatment over a period of 2 to 4 months for each patient.","dispersionType":"Standard Deviation","groups":[{"description":"All eligible subjects that underwent up to 5 treatments at 4±1-week intervals to the vulva with a fractional CO2 laser and maintained the protocol regimen.\n\nThe CO2RE® System: The CO2RE® system is a fractional CO2 laser that is FDA-cleared under a 510(k) K181523 for laser incision, excision, ablation and/or vaporization and of soft tissue in gynecology (GYN).","id":"OG000","title":"CO2RE® Treatment"}],"paramType":"MEAN","populationDescription":"A total of 57 sessions were conducted (10 subjects had 5 treatments,1 subject had 4 treatments and 1 subject had 3 treatments)","reportingStatus":"POSTED","timeFrame":"Immediately after the 1st, 2nd, 3rd, 4th and 5th monthly treatments post baseline","title":"Treatment Associated Pain Score","type":"SECONDARY","typeUnitsAnalyzed":"Number of Treatments","unitOfMeasure":"score on a scale"}